The company has two divisions: Pharma, which focuses its activity on the development of innovative drugs through the search for new applications for already-known molecules, and Services and Reagents, which uses cell-based in vitro methods to predict the efficacy, safety and mechanism of action of developing molecules. Advancell's business model allows it to achieve substantial reductions in costs, risks and the development time of a drug.
Advancell is a world leader in nanomedicine, the science that uses technologies at the nanometric (less then a millionth of a millimeter) scale to diagnose, treat and prevent diseases. The most advanced project is focused on nanomedicines for the topical treatment of psoriasis and other skin diseases. In addition, Advancell is developing a new "orphan drug" for Chronic Lymphocytic Leukaemia and an adjuvant treatment for depression, which is currently in the clinical phase II.
The Services and Reagents Unit develops and markets in vitro cell models with a regulatory and/or predictive value. Our R&D efforts are focused on the development of new in vitro cell-based models and kits targeting skin ADME/Tox and skin biology. We are experts in epithelial and mucosal barrier models, as well as in hepatic metabolism and toxicity. Our ready-to-use reagent line (www.cacoready.com) is distributed all over Europe.
Our company is located in Barcelona's "Parc Científic" and has research centres at Santiago de Compostela University and Hospital La Fe, in Valencia.
Parc Cientific de Barcelona, Baldiri i Reixach 10-12,